Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of YZJ-1139 in Severe Renal Impairment
NCT06671444Phase 1Completed
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fazamorexant in Insomnia (2 arms), sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration, Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity and 9 more. Started Jun 2024; status: completed.
02
Drugs
fazamorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06671444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671444.